Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

The right dosage of CPA and TB can work as a safe and reversible male contraceptive in monkeys.

Agomelatine might help reduce hair loss caused by valproate.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Anti-epileptic drugs may cause visual and hair side effects due to enzyme inhibition, especially in genetically predisposed individuals.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

Bimatoprost shows promise for treating vitiligo, especially when combined with other therapies.

Prednisolone and Bactrim improved symptoms in a woman with Cronkhite-Canada syndrome.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Two women experienced temporary hair loss and other side effects from imiquimod treatment for cervical issues, which stopped after ending the treatment.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

A three-year-old girl survived a rare serious infection caused by BCG vaccination, which improved after treatment with a leprosy drug.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Vemurafenib can cause scalp issues but can be managed without changing the dose.